The vaccine against Covid-19 developed by the French laboratory Sanofi, in collaboration with the British GSK, should be available in December, said the French president of the laboratory, on Monday.
Asked about France Inter on the availability of this recombinant protein-based vaccine - a technology already used by Sanofi for one of its influenza vaccines - Olivier Bogillot confirmed that he would be ready in “December”.
The group had previously indicated to count on the fourth quarter, then specified to envisage a provision by the end of the year.
First clinical trials started
This vaccine, now in the phase of massive trials, called phase 3, had been delayed by several months, causing controversy.
At the same time, Sanofi is developing another vaccine against Covid, based on messenger RNA technology, with an American partner, the startup Translate Bio.
They have started the first clinical trials which should give their results in the third trimester.
These are already messenger RNA vaccines that were among the first to be distributed in early 2021 against Covid-19, those of Pfizer and Moderna.
Health
Coronavirus: "Any unvaccinated person will be infected with the Delta variant", according to a director of the ARS
World
United States: During the national holiday, Joe Biden recalls that the coronavirus is not yet "defeated"
epidemic
Anti-covid vaccine
Covid 19
Coronavirus
Vaccination
Health